Upadacitinib After TNF Inhibitor Failure Improves RA Control
A recent study found that switching to upadacitinib after failing a TNF inhibitor significantly improved disease control in rheumatoid arthritis patients compared to cycling to adalimumab. At 12 weeks, a higher percentage of patients on upadacitinib achieved low disease activity with similar safety profiles between the two treatments. The study highlights the importance of personalized treatment decisions based on individual patient profiles and ongoing research for long-term efficacy and safety.
- ▪Switching to upadacitinib resulted in superior disease control compared to cycling to adalimumab.
- ▪At week 12, 43.3% of patients on upadacitinib achieved a Disease Activity Score in 28 joints using CRP ≤ 3.2, compared to 22.4% on adalimumab.
- ▪The study was conducted across 218 sites in 24 countries with 491 patients participating.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/switch-upadacitinib-vs-adalimumab-after-tnf-inhibitor-2026a1000dkx?src=rss |
| Publication time | Wed, 29 Apr 2026 05:00:31 EDT |
| Retrieval time | 2026-04-29T09:06:54.500Z |
| Last seen | 2026-04-29T09:06:54.500Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | mzy-ElF0cXwi |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Switching to upadacitinib after failure of a first TNF inhibitor resulted in superior disease control compared with cycling to adalimumab in patients with rheumatoid arthritis (RA). At 12 weeks, more patients receiving upadacitinib achieved low disease activity, with comparable safety profiles between treatments.METHODOLOGY:Researchers conducted a randomized phase 3b/4 trial across 218 sites in 24 countries to determine whether switching to a JAK inhibitor or cycling to another TNF inhibitor would be more efficacious for patients with active RA who previously had an inadequate response or intolerance to a single non-adalimumab TNF inhibitor while receiving stable methotrexate.A total of 491 patients (mean age, 55.6 years; 77.4% female) were randomly assigned to receive either 15…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
